Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Liu, Joan ^a   Reeves, Cheryl ^a   Michalak, Zuzanna ^a   Coppola, Antonietta ^a   Diehl, Beate ^a   Sisodiya, Sanjay M ^a   Thom, Maria ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Epilepsy; Hippocampal sclerosis; MTOR pathway; Neuronal dysplasia; Rasmussen's' encephalitis

Indexed keywords

AIF1 PROTEIN, HUMAN; DNA BINDING PROTEIN; DOUBLECORTIN PROTEIN; LEUKOCYTE ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; MTOR PROTEIN, HUMAN; NEUROPEPTIDE; PROTEIN S6; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; BRAIN CORTEX; CHILD; COMPLICATION; CORTICAL DYSPLASIA; EPILEPSY; FEMALE; HUMAN; INTERMEDIATE FILAMENT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD; CEREBRAL CORTEX; CHILD; DNA-BINDING PROTEINS; EPILEPSY; FEMALE; HUMANS; INTERMEDIATE FILAMENTS; MALE; MALFORMATIONS OF CORTICAL DEVELOPMENT; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEUROPEPTIDES; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 84912135993     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-71     Document Type: Article

References (53)

1. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, Jacques TS, Avanzini G, Barkovich AJ, Battaglia G, Becker A, Cepeda C, Cendes F, Colombo N, Crino P, Cross JH, Delalande O, Dubeau F, Duncan J, Guerrini R, Kahane P, Mathern G, Najm I, Ozkara C, Raybaud C, Represa A, Roper SN, Salamon N, Schulze-Bonhage A, Tassi L, et al.: The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011, 52(1):158-174. doi:10.1111/j.1528-1167.2010.02777.x
2. Napolioni V, Moavero R, Curatolo P: Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev 2009, 31(2):104-113. doi:10.1016/j.braindev.2008.09.013
3. Baybis M, Yu J, Lee A, Golden JA, Weiner H, McKhann G 2nd, Aronica E, Crino PB: mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol 2004, 56(4):478-487.
4. Crino PB: mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011, 17(12):734-742. doi:10.1016/j.molmed.2011.07.008
5. Lim KC, Crino PB: Focal malformations of cortical development: new vistas for molecular pathogenesis. Neuroscience 2013, 252: 262-276. doi:10.1016/j.neuroscience.2013.07.037
6. Miyata H, Chiang AC, Vinters HV: Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann Neurol 2004, 56(4):510-519.
7. Wong M: A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Rev Neurother 2013, 13(6):657-669. doi:10.1586/ern.13.48
8. Alayev A, Holz MK: mTOR signaling for biological control and cancer. J Cell Physiol 2013, 228(8):1658-1664. doi:10.1002/jcp.24351
9. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945. doi:10.1101/gad.1212704
10. Laplante M, Sabatini DM: mTOR signaling at a glance. J Cell Sci 2009, 122(Pt 20):3589-3594. doi:10.1242/jcs.051011
11. Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, Nicholson SL, Harkness W, Cross JH, Paine SM, Jacques TS: mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. Acta Neuropathol 2013, 126(2):207-218. doi:10.1007/s00401-013-1135-4
12. Kim SH, Cho YJ, Seok Kim H, Heo K, Lee MC, Lee BI, Seung Kim T, Woo Chang J: Balloon cells and dysmorphic neurons in the hippocampus associated with epileptic amnesic syndrome: a case report. Epilepsia 2008, 49(5):905-909. doi:10.1111/j.1528-1167.2007.01527.x
13. Miyahara H, Ryufuku M, Fu YJ, Kitaura H, Murakami H, Masuda H, Kameyama S, Takahashi H, Kakita A: Balloon cells in the dentate gyrus in hippocampal sclerosis associated with non-herpetic acute limbic encephalitis. Seizure 2011, 20(1):87-89. doi:10.1016/j.seizure.2010.09.013
14. Thom M, D'Arrigo C, Scaravilli F: Hippocampal sclerosis with hypertrophy of end folium pyramidal cells. Acta Neuropathol 1999, 98(1):107-110.
15. Thom M, Martinian L, Caboclo LO, McEvoy AW, Sisodiya SM: Balloon cells associated with granule cell dispersion in the dentate gyrus in hippocampal sclerosis. Acta Neuropathol 2008, 115(6):697-700. doi:10.1007/s00401-008-0341-y
16. Blumcke I, Zuschratter W, Schewe JC, Suter B, Lie AA, Riederer BM, Meyer B, Schramm J, Elger CE, Wiestler OD: Cellular pathology of hilar neurons in Ammon's horn sclerosis. J Comp Neurol 1999, 414(4):437-453.
17. Hart YM, Andermann F, Robitaille Y, Laxer KD, Rasmussen T, Davis R: Double pathology in Rasmussen's syndrome: a window on the etiology? Neurology 1998, 50(3):731-735.
18. Prayson RA: Dual pathology in rasmussen's encephalitis: a report of coexistent focal cortical dysplasia and review of the literature. Case Rep Pathol 2012, 2012: 569170. doi:10.1155/2012/569170
19. Takei H, Wilfong A, Malphrus A, Yoshor D, Hunter JV, Armstrong DL, Bhattacharjee MB: Dual pathology in Rasmussen's encephalitis: a study of seven cases and review of the literature. Neuropathology 2010, 30(4):381-391. doi:10.1111/j.1440-1789.2009.01079.x
20. Sha LZ, Xing XL, Zhang D, Yao Y, Dou WC, Jin LR, Wu LW, Xu Q: Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy. PLoS One 2012, 7(6):e39152. doi:10.1371/journal.pone.0039152
21. Sosunov AA, Wu X, McGovern RA, Coughlin DG, Mikell CB, Goodman RR, McKhann GM 2nd: The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia 2012, 53(Suppl 1):78-86. doi:10.1111/j.1528-1167.2012.03478.x
22. Blumcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi A, Bernasconi N, Bien CG, Cendes F, Coras R, Cross JH, Jacques TS, Kahane P, Mathern GW, Miyata H, Moshe SL, Oz B, Ozkara C, Perucca E, Sisodiya S, Wiebe S, Spreafico R: International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 2013, 54(7):1315-1329. doi:10.1111/epi.12220
23. Liu JY, Thom M, Catarino CB, Martinian L, Figarella-Branger D, Bartolomei F, Koepp M, Sisodiya SM: Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012, 135(Pt 10):3115-3133. doi:10.1093/brain/aws147
24. Goc J, Liu JY, Sisodiya SM, Thom M: A spatiotemporal study of gliosis in relation to depth electrode tracks in drug-resistant epilepsy. Eur J Neurosci 2014. doi:10.1111/ejn.12548
25. Anjum R, Blenis J: The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008, 9(10):747-758. doi:10.1038/nrm2509
26. Thom M, Eriksson S, Martinian L, Caboclo LO, McEvoy AW, Duncan JS, Sisodiya SM: Temporal lobe sclerosis associated with hippocampal sclerosis in temporal lobe epilepsy: neuropathological features. J Neuropathol Exp Neurol 2009, 68(8):928-938. doi:10.1097/NEN.0b013e3181b05d67
27. Prabowo AS, Iyer AM, Veersema TJ, Anink JJ, Schouten-van Meeteren AY, Spliet WG, van Rijen PC, Ferrier CH, Capper D, Thom M, Aronica E: BRAF V600E mutation is associated with mTOR Signaling activation in glioneuronal tumors. Brain Pathol 2013. doi:10.1111/bpa.12081
28. Orlova KA, Tsai V, Baybis M, Heuer GG, Sisodiya S, Thom M, Strauss K, Aronica E, Storm PB, Crino PB: Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropathol Exp Neurol 2010, 69(8):850-863. doi:10.1097/NEN.0b013e3181eac1f5
29. Ljungberg MC, Bhattacharjee MB, Lu Y, Armstrong DL, Yoshor D, Swann JW, Sheldon M, D'Arcangelo G: Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol 2006, 60(4):420-429. doi:10.1002/ana.20949
30. Maiese K, Chong ZZ, Shang YC, Wang S: mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med 2013, 19(1):51-60. doi:10.1016/j.molmed.2012.11.001
31. Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S, Perreault C, Roux PP, Kitano H: A comprehensive map of the mTOR signaling network. Mol Syst Biol 2010, 6: 453. doi:10.1038/msb.2010.108
32. Chen J, Tsai V, Parker WE, Aronica E, Baybis M, Crino PB: Detection of human papillomavirus in human focal cortical dysplasia type IIB. Ann Neurol 2012, 72(6):881-892. doi:10.1002/ana.23795
33. Scheffer IE, Heron SE, Regan BM, Mandelstam S, Crompton DE, Hodgson BL, Licchetta L, Provini F, Bisulli F, Vadlamudi L, Gecz J, Connelly A, Tinuper P, Ricos MG, Berkovic SF, Dibbens LM: Mutations in mTOR regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 2014. doi:10.1002/ana.24126
34. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, Heinzen EL, Hitomi Y, Howell KB, Johnson MR, Kuzniecky R, Lowenstein DH, Lu YF, Madou MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O'Brien TJ, Ottman R, Petrovski S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil B, et al.: De novo mutations in epileptic encephalopathies. Nature 2013, 501(7466):217-221. doi:10.1038/nature12439
35. Coras R, de Boer OJ, Armstrong D, Becker A, Jacques TS, Miyata H, Thom M, Vinters HV, Spreafico R, Oz B, Marucci G, Pimentel J, Muhlebner A, Zamecnik J, Buccoliero AM, Rogerio F, Streichenberger N, Arai N, Bugiani M, Vogelgesang S, Macaulay R, Salon C, Hans V, Polivka M, Giangaspero F, Fauziah D, Kim JH, Liu L, Dandan W, Gao J, et al.: Good interobserver and intraobserver agreement in the evaluation of the new ILAE classification of focal cortical dysplasias. Epilepsia 2012, 53(8):1341-1348. doi:10.1111/j.1528-1167.2012.03508.x
36. Pun RY, Rolle IJ, Lasarge CL, Hosford BE, Rosen JM, Uhl JD, Schmeltzer SN, Faulkner C, Bronson SL, Murphy BL, Richards DA, Holland KD, Danzer SC: Excessive activation of mTOR in postnatally generated granule cells is sufficient to cause epilepsy. Neuron 2012, 75(6):1022-1034. doi:10.1016/j.neuron.2012.08.002
37. Varadkar S, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, Vincent A, Mathern GW, Cross JH: Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 2014, 13(2):195-205. doi:10.1016/S1474-4422(13)70260-6
38. Thomson AW, Turnquist HR, Raimondi G: Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009, 9(5):324-337. doi:10.1038/nri2546
39. McDaniel SS, Wong M: Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett 2011, 497(3):231-239. doi:10.1016/j.neulet.2011.02.037
40. Sato A, Sunayama J, Matsuda K, Tachibana K, Sakurada K, Tomiyama A, Kayama T, Kitanaka C: Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR. Neurosci Lett 2010, 470(2):115-120. doi:10.1016/j.neulet.2009.12.067
41. Siebzehnrubl FA, Blumcke I: Neurogenesis in the human hippocampus and its relevance to temporal lobe epilepsies. Epilepsia 2008, 49(Suppl 5):55-65. doi:10.1111/j.1528-1167.2008.01638.x
42. Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AH, Verveer M, de Groot LR, Smith VD, Rangarajan S, Rodriguez JJ, Orre M, Hol EM: GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 2012, 7(8):e42823. doi:10.1371/journal.pone.0042823
43. Martinian L, Boer K, Middeldorp J, Hol EM, Sisodiya SM, Squier W, Aronica E, Thom M: Expression patterns of glial fibrillary acidic protein (GFAP)-delta in epilepsy-associated lesional pathologies. Neuropathol Appl Neurobiol 2009, 35(4):394-405. doi:10.1111/j.1365-2990.2009.00996.x
44. Boer K, Troost D, Timmermans W, van Rijen PC, Spliet WG, Aronica E: Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 2010, 20(1):234-244. doi:10.1111/j.1750-3639.2009.00268.x
45. Meng XF, Yu JT, Song JH, Chi S, Tan L: Role of the mTOR signaling pathway in epilepsy. J Neurol Sci 2013, 332(1-2):4-15. doi:10.1016/j.jns.2013.05.029
46. Abs E, Goorden SM, Schreiber J, Overwater IE, Hoogeveen-Westerveld M, Bruinsma CF, Aganovic E, Borgesius NZ, Nellist M, Elgersma Y: TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice. Ann Neurol 2013, 74(4):569-579. doi:10.1002/ana.23943
47. Huang X, Zhang H, Yang J, Wu J, McMahon J, Lin Y, Cao Z, Gruenthal M, Huang Y: Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 2010, 40(1):193-199. doi:10.1016/j.nbd.2010.05.024
48. Berdichevsky Y, Dryer AM, Saponjian Y, Mahoney MM, Pimentel CA, Lucini CA, Usenovic M, Staley KJ: PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. J Neurosci 2013, 33(21):9056-9067. doi:10.1523/JNEUROSCI.3870-12.2013
49. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS: A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 2011, 43(2):322-329. doi:10.1016/j.nbd.2011.03.021
50. Buckmaster PS, Ingram EA, Wen X: Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci 2009, 29(25):8259-8269. doi:10.1523/JNEUROSCI.4179-08.2009
51. Zeng LH, Xu L, Gutmann DH, Wong M: Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63(4):444-453. doi:10.1002/ana.21331
52. Wong M: Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Exp Neurol 2013, 244: 22-26. doi:10.1016/j.expneurol.2011.10.002
53. Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczynski D, Kmiec T, Lojszczyk B, Dunin-Wasowicz D, Jozwiak S: Long-term effect of everolimus on epilepsy and growth in children under 3years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 2013, 17(5):479-485. doi:10.1016/j.ejpn.2013.03.002